# V1 Empirics Check — qwen/qwen3.5-397b-a17b (Variant C)

**Model:** qwen/qwen3.5-397b-a17b
**Variant:** C
**Date:** 2026-04-01T10:46:59.654131

---

# Review: The Coverage-to-Care Gap: Medicaid Doula Reimbursement and Population-Level Birth Outcomes

## 1. Idea Fidelity
The paper largely adheres to the core empirical strategy outlined in the Original Idea Manifest but deviates in key design parameters that affect statistical power. The Manifest proposed using 15+ states with adoption between 2014–2024 and data through 2024. The submitted paper restricts the sample to 8 states adopting between 2022–2023 and data through 2023. While the exclusion of 2014 adopters (Oregon, Minnesota) is justified by the author as avoiding "different adoption regimes," and the 2024 cohort is excluded due to data availability, these decisions halve the proposed treatment group and shorten the post-period. Consequently, the analysis relies on a much narrower window of variation than originally planned. However, the core identification strategy (staggered DiD with Callaway-Sant'Anna), data source (NCHS Natality), and research question (population-level ITT vs. individual efficacy) remain faithful to the Manifest.

## 2. Summary
This paper provides the first population-level estimate of Medicaid doula reimbursement mandates on birth outcomes, exploiting staggered state adoption between 2022 and 2023. Using 17.2 million birth records, the author finds a statistically insignificant 0.19 percentage point reduction in C-section rates, suggesting a "coverage-to-care gap" where financial coverage fails to translate into utilization due to supply-side constraints. The study makes a valuable conceptual contribution by distinguishing between individual efficacy and population-level intention-to-treat effects in maternal health policy.

## 3. Essential Points
The authors must address the following three issues to ensure the validity of the null result:

1.  **Inference with Few Treated Clusters:** The analysis clusters standard errors at the state level with only 8 treated states and 41 control states. With如此 few treated units, conventional asymptotic inference is unreliable and prone to size distortion. The paper requires robust inference methods suitable for few clusters, such as a wild cluster bootstrap or permutation tests, to confirm that the null result is not an artifact of underestimated standard errors or low power.
2.  **Significant Pre-Trend at *t*-3:** The event study (\Cref{tab:eventstudy}) shows a statistically significant coefficient at $t-3$ (-0.51 pp, $p < 0.01$). While the author notes this in the robustness section, a significant pre-trend violates the parallel trends assumption underlying DiD. Given the small number of treated states, this could be driven by a single outlier state. The authors must demonstrate that this pre-trend is not systematic or adjust the identification strategy (e.g., state-specific trends or dropping the driving state) to validate the counterfactual.
3.  **Power and Minimum Detectable Effect (MDE):** Given the null result, it is critical to report the Minimum Detectable Effect size. If the MDE is larger than the clinically meaningful threshold (e.g., the 12.7 pp reduction implied by individual studies scaled by realistic take-up), the paper cannot confidently claim the effect is zero; it may simply be underpowered. A formal power analysis is necessary to distinguish between "no effect" and "no evidence of an effect."

## 4. Suggestions
The following recommendations are intended to strengthen the paper's econometric rigor and policy relevance. While not strictly fatal if unaddressed, attending to these points will significantly improve the manuscript's contribution to the literature.

**Strengthening Inference and Power Analysis**
With only 8 treated states, the risk of false negatives is high. I recommend implementing a wild cluster bootstrap (e.g., `cgmboot` or `wildcluster` in Stata/R) to generate p-values and confidence intervals. This method performs better than asymptotic clustering when the number of groups is small. Additionally, include a formal power calculation. Based on the variance of state-level C-section rates and the sample size, what is the smallest effect size the study can detect with 80% power? If the MDE is 0.5 pp but the true effect is 0.2 pp, the null result is uninformative. Explicitly stating this bound helps policymakers understand the precision of the estimate.

**Investigating the Pre-Trend Anomaly**
The significant pre-trend at $t-3$ warrants deeper investigation than a sensitivity citation. Since the paper uses aggregated state-year data, it is computationally inexpensive to produce a "leave-one-state-out" event study plot. If removing one state (e.g., Virginia or Maryland) eliminates the pre-trend, this should be reported transparently. Alternatively, consider including state-specific linear trends in the triple-difference specification. If the result holds with state-specific trends, it bolsters the claim that the parallel trends assumption holds conditionally.

**Exploiting Reimbursement Heterogeneity**
The paper mentions reimbursement rates range from \$450 to \$3,263 but does not exploit this variation in the main analysis. This is a missed opportunity to validate the "coverage-to-care" mechanism. If supply constraints drive the null result, states with higher reimbursement rates (e.g., California) should exhibit larger effects than low-reimbursement states (e.g., Florida/Oklahoma). I suggest adding a heterogeneity analysis interacting the treatment indicator with reimbursement levels. A positive correlation would provide direct evidence supporting the supply-side constraint hypothesis, transforming a null result into a nuanced policy lesson.

**Refining the Triple-Difference Control**
The triple-difference uses private-insurance births as a control. However, private insurers often follow Medicaid policy changes, or hospital-wide culture changes (e.g., labor management protocols) might affect both groups simultaneously. While the DDD absorbs state-level shocks, ensure that the "private" group is not contaminated by spillovers. For instance, if hospitals hire more doulas due to Medicaid policy, private patients might also access them. A falsification test using a state where private insurance already covered doulas (if any exist) or checking for changes in private-market doula advertising volume could help rule out spillovers.

**Clarifying the Standardized Effect Size Table**
The Appendix table classifies the C-section effect as "Large negative" based on an SDE of -0.273. This is confusing messaging for a paper emphasizing a null result. Standard conventions (e.g., Cohen's d) often treat 0.2 as small. Moreover, classifying an insignificant estimate as "Large" based solely on the point estimate magnitude relative to SD may mislead readers about the certainty of the finding. I recommend removing the "Classification" column
